Mok K, Tomtong P, Ogawa T et al (2025) Synbiotic-driven modulation of the gut microbiota and metabolic functions related to obesity: insights from a human Gastrointestinal model
Dec 18, 2025, 08:00 ET CagriSema 2.4 mg/2.4 mg is an investigational fixed-dose injectable medicine that combines the novel amylin analogue, cagrilintide, with semaglutide to target complementary obesity-related pathways 1,2 In the REDEFINE 1 phase 3 trial, adults with obesity, or overweight with at least one obesity-related complication, taking CagriSema lost an average of 23% body weight when evaluating the treatment effect if all patients stayed on treatment *2 Novo Nordisk continues to build on its 100-year-plus legacy of science and innovation, with potential new treatments in obesity PLAINSBORO, N.J
Related Podcasts: Child Development & Nutrition | COVID-19 Pandemic Impacts on Food | Equity, Race & Food Justice | Food Insecurity | Food Policy | Social Safety Net & Food | February 23, 2023 Artificial sweeteners, known more recently as non-nutritive or low-calorie sweeteners, have been a source of great hope
Common symptoms include: Dry mouth or extreme thirst
